James Doroshow

Division of Cancer Treatment and Diagnosis, National Institutes of Health

Affiliated withNational Institutes of Health

Research Area

Biography

James Doroshow has not added Biography.
If you are James Doroshow and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 2	2025

Other Publications

Article	Year
Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. The Journal of biological chemistry\| PubMed ID: 16956884	2006
Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochemical pharmacology\| PubMed ID: 17445777	2007
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 19364967	2009
Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free radical research\| PubMed ID: 19431059	2009
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. Journal of the National Cancer Institute\| PubMed ID: 20944079	2010
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature reviews. Drug discovery\| PubMed ID: 21031001	2010
Up-regulation and sustained activation of Stat1 are essential for interferon-gamma (IFN-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (DuoxA2) expression in human pancreatic canc... The Journal of biological chemistry\| PubMed ID: 21321110	2011
Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas. Anticancer research\| PubMed ID: 21498721	2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer research\| PubMed ID: 21795476	2011
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell cycle (Georgetown, Tex.)\| PubMed ID: 22101337	2011
Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. Biochemical pharmacology\| PubMed ID: 22305747	2012
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22307137	2012
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 22927417	2012
Analysis of candidate colitis genes in the Gdac1 locus of mice deficient in glutathione peroxidase-1 and -2. PloS one\| PubMed ID: 22970191	2012
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer research\| PubMed ID: 23118055	2012
Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 23296709	2013
Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cel... Free radical biology & medicine\| PubMed ID: 23314043	2013
Safety and feasibility of targeted agent combinations in solid tumours. Nature reviews. Clinical oncology\| PubMed ID: 23358316	2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23403637	2013
Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody. International journal of oncology\| PubMed ID: 23404210	2013
Cediranib for metastatic alveolar soft part sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 23630200	2013
Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? The oncologist\| PubMed ID: 23814160	2013
Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody. Free radical biology & medicine\| PubMed ID: 23851018	2013
Timely completion of scientifically rigorous cancer clinical trials: an unfulfilled priority. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 23960175	2013
Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer letters\| PubMed ID: 23988267	2014
The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 genes. Free radical biology & medicine\| PubMed ID: 24090658	2013
Criteria for the use of omics-based predictors in clinical trials. Nature\| PubMed ID: 24132288	2013
NADPH oxidases: a perspective on reactive oxygen species production in tumor biology. Antioxidants & redox signaling\| PubMed ID: 24156355	2014
Overcoming resistance to targeted anticancer drugs. The New England journal of medicine\| PubMed ID: 24180495	2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC medicine\| PubMed ID: 24228635	2013
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Molecular cancer therapeutics\| PubMed ID: 24356813	2014
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 24650937	2014
Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA repair\| PubMed ID: 24794403	2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. Journal of the National Cancer Institute\| PubMed ID: 24842883	2014
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting\| PubMed ID: 24857062	2014
Molecular analysis for therapy choice: NCI MATCH. Seminars in oncology\| PubMed ID: 25023344	2014
NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PloS one\| PubMed ID: 25032700	2014
National Cancer Institute-supported clinical trials networks. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 25452448	2015
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25589624	2015
Notch1 phenotype and clinical stage progression in non-small cell lung cancer. Journal of hematology & oncology\| PubMed ID: 25653136	2015
NADPH oxidases and cancer. Clinical science (London, England : 1979)\| PubMed ID: 25818486	2015
Defects in NADPH Oxidase Genes and in Very Early Onset Inflammatory Bowel Disease. Cellular and molecular gastroenterology and hepatology\| PubMed ID: 26301257	2015
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational new drugs\| PubMed ID: 26996385	2016
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of experimental & clinical cancer research : CR\| PubMed ID: 27029323	2016
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 27169793	2016
Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Seminars in oncology\| PubMed ID: 27663476	2016
Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Seminars in oncology\| PubMed ID: 27663483	2016
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs\| PubMed ID: 28078645	2017
NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction. The Journal of biological chemistry\| PubMed ID: 28330872	2017
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 28350521	2017
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. Cancer research\| PubMed ID: 28446463	2017
Decoding NADPH oxidase 4 expression in human tumors. Redox biology\| PubMed ID: 28578276	2017
Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. Biochemical pharmacology\| PubMed ID: 28709950	2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. Investigational new drugs\| PubMed ID: 28808818	2018
On the Design of Combination Cancer Therapy. Cell\| PubMed ID: 29245008	2017
The Partnership for Accelerating Cancer Therapies. Cancer journal (Sudbury, Mass.)\| PubMed ID: 30273184	2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. Cancer research\| PubMed ID: 30355619	2018
Modernizing Clinical Trials for Patients With Cancer. JAMA\| PubMed ID: 30673081	2019
RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. Cancer research\| PubMed ID: 31113817	2019
Guidelines for the Detection of NADPH Oxidases by Immunoblot and RT-qPCR. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 31172474	2019
Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells... Free radical research\| PubMed ID: 31290351	2019
From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer journal (Sudbury, Mass.)\| PubMed ID: 31335388	2019
IL-4 and IL-17A Cooperatively Promote Hydrogen Peroxide Production, Oxidative DNA Damage, and Upregulation of Dual Oxidase 2 in Human Colon and Pancreatic Cancer Cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 31548328	2019
Dexamethasone and Tofacitinib suppress NADPH oxidase expression and alleviate very-early-onset ileocolitis in mice deficient in GSH peroxidase 1 and 2. Life sciences\| PubMed ID: 31689440	2019
Genomics and the History of Precision Oncology. Surgical oncology clinics of North America\| PubMed ID: 31757312	2020
State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 32134701	2020
Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis. Cancer research\| PubMed ID: 32152150	2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 32314030	2020
Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells. Reactive oxygen species (Apex, N.C.)\| PubMed ID: 32337366	2020
COVID-19, Social Justice, and Clinical Cancer Research. Journal of the National Cancer Institute\| PubMed ID: 33057660	2021
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget\| PubMed ID: 33216844	2020
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 33419780	2021
The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell\| PubMed ID: 33798439	2021
TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models. Journal of hematology & oncology\| PubMed ID: 34039392	2021
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. Cancer discovery\| PubMed ID: 34290074	2021
ATR inhibition reverses the resistance of homologous recombination deficient MGMT/MMR cancer cells to temozolomide. Oncotarget\| PubMed ID: 34676045	2021
Effects of Iodonium Analogs on Nadph Oxidase 1 in Human Colon Cancer Cells. Antioxidants (Basel, Switzerland)\| PubMed ID: 34829628	2021
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. OncoTargets and therapy\| PubMed ID: 35237050	2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 35263120	2022
Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers. Cancer journal (Sudbury, Mass.)\| PubMed ID: 35333495	2022
The beginning of GPX2 and 30 years later. Free radical biology & medicine\| PubMed ID: 35803440	2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet (London, England)\| PubMed ID: 35964611	2022
3'-[F]fluoro-3'-deoxythymidine ([F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor. Journal of translational medicine\| PubMed ID: 35982453	2022
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 36662819	2023
Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway. Free radical biology & medicine\| PubMed ID: 37330147	2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 38010394	2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Molecular cancer therapeutics\| PubMed ID: 38641411	2024
The DNA Methyltransferase Inhibitor 5-Aza-4'-thio-2'-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development. Cancer research\| PubMed ID: 38832931	2024
Upregulation of TET2 and Resistance to DNA Methyltransferase (DNMT) Inhibitors in -Deleted Cancer Cells. Diseases (Basel, Switzerland)\| PubMed ID: 39057134	2024
NCI workshop on ctDNA in cancer treatment and clinical care. Journal of the National Cancer Institute\| PubMed ID: 39087596	2024
Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor. SLAS discovery : advancing life sciences R & D\| PubMed ID: 39362362	2024
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export. Nature cancer\| PubMed ID: 39528835	2024
Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth. bioRxiv : the preprint server for biology\| PubMed ID: 39605563	2024
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nature medicine\| PubMed ID: 39762421	2025
Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids. SLAS discovery : advancing life sciences R & D\| PubMed ID: 39999911	2025
Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids. SLAS discovery : advancing life sciences R & D\| PubMed ID: 40210129	2025
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. Cancer chemotherapy and pharmacology\| PubMed ID: 40439882	2025